iBio, Inc. Files 8-K Report
Ticker: IBIO · Form: 8-K · Filed: Nov 4, 2025 · CIK: 1420720
| Field | Detail |
|---|---|
| Company | Ibio, Inc. (IBIO) |
| Form Type | 8-K |
| Filed Date | Nov 4, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-info, 8-K
TL;DR
iBio filed an 8-K, updating its address and former names. Nothing major, just housekeeping.
AI Summary
On November 4, 2025, iBio, Inc. filed an 8-K report. The filing indicates that the company is located at 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121, and its telephone number is (979) 446-0027. The company was formerly known as iBioPharma, Inc. and InB:Biotechnologies, Inc.
Why It Matters
This filing provides updated corporate information for iBio, Inc., including its current address and former names, which is important for investors and stakeholders to maintain accurate records.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting corporate information and does not disclose any new material events, financial changes, or strategic shifts.
Key Players & Entities
- iBio, Inc. (company) — Registrant
- 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121 (location) — Principal executive offices
- iBioPharma, Inc. (company) — Former name
- InB:Biotechnologies, Inc. (company) — Former name
FAQ
What is the primary purpose of this 8-K filing for iBio, Inc.?
The primary purpose of this 8-K filing is to report current information about the registrant, iBio, Inc., including its principal executive offices and former names.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on November 4, 2025.
What is iBio, Inc.'s current principal executive office address?
iBio, Inc.'s current principal executive office is located at 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121.
What were iBio, Inc.'s former names?
iBio, Inc. was formerly known as iBioPharma, Inc. and InB:Biotechnologies, Inc.
What is the company's telephone number as listed in the filing?
The company's telephone number is (979) 446-0027.
Filing Stats: 456 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2025-11-04 16:03:09
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share IBIO The Nasdaq
- $1.00 — maintain a minimum closing bid price of $1.00 per share over the previous 30 consecut
Filing Documents
- ibio-20251104x8k.htm (8-K) — 27KB
- 0001420720-25-000035.txt ( ) — 142KB
- ibio-20251104.xsd (EX-101.SCH) — 3KB
- ibio-20251104_def.xml (EX-101.DEF) — 3KB
- ibio-20251104_lab.xml (EX-101.LAB) — 17KB
- ibio-20251104_pre.xml (EX-101.PRE) — 11KB
- ibio-20251104x8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On November 4, 2025, iBio, Inc. (the "Company") received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") noting it has regained compliance with Nasdaq Lising Rule 5550(a)(2). As previously reported, on July 29, 2025, the Company received a letter from Nasdaq indicating the Company was not in compliance with the Nasdaq Listing Rule 5550(a)(2) because the Company's common stock failed to maintain a minimum closing bid price of $1.00 per share over the previous 30 consecutive business days (June 13, 2025 to July 28, 2025), as required by Nasdaq Listing Rule 5550(a)(2). The matter is now closed.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 4, 2025 IBIO, INC. By: /s/ Marc A. Banjak Name: Marc A. Banjak Title: Chief Legal Counsel